Stratos Wealth Partners LTD. Invests $112,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Stratos Wealth Partners LTD. purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 16,553 shares of the company’s stock, valued at approximately $112,000.

Several other institutional investors have also added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals in the third quarter valued at $25,000. Decker Retirement Planning Inc. purchased a new position in shares of Recursion Pharmaceuticals in the 4th quarter worth $26,000. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock worth $35,000 after buying an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC raised its position in shares of Recursion Pharmaceuticals by 176.9% during the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock valued at $42,000 after buying an additional 4,091 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Recursion Pharmaceuticals by 79.9% in the 3rd quarter. KBC Group NV now owns 7,602 shares of the company’s stock valued at $50,000 after acquiring an additional 3,377 shares during the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Stock Up 23.9 %

Shares of NASDAQ RXRX opened at $10.53 on Friday. Recursion Pharmaceuticals, Inc. has a 1 year low of $5.60 and a 1 year high of $15.74. The firm has a 50-day simple moving average of $7.27 and a two-hundred day simple moving average of $6.92. The company has a market cap of $4.11 billion, a P/E ratio of -6.88 and a beta of 0.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on RXRX. Needham & Company LLC reissued a “buy” rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, February 6th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.